Cargando…
Low levels of the key B cell activation marker, HLA-DR, in COVID-19 hospitalized cases are associated with disease severity, dexamethasone treatment, and circulating IL-6 levels
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9178219/ https://www.ncbi.nlm.nih.gov/pubmed/35679009 http://dx.doi.org/10.1007/s12026-022-09269-w |
| _version_ | 1784723011317792768 |
|---|---|
| author | Dobi, Anthony Dubernet, Arthur Rakoto, Mahary Lalarizo Seteyen, Anne-Laure Sandenon Vagner, Damien Lebeau, Grégorie Raffray, Loïc Gasque, Philippe |
| author_facet | Dobi, Anthony Dubernet, Arthur Rakoto, Mahary Lalarizo Seteyen, Anne-Laure Sandenon Vagner, Damien Lebeau, Grégorie Raffray, Loïc Gasque, Philippe |
| author_sort | Dobi, Anthony |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9178219 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Springer US |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-91782192022-06-09 Low levels of the key B cell activation marker, HLA-DR, in COVID-19 hospitalized cases are associated with disease severity, dexamethasone treatment, and circulating IL-6 levels Dobi, Anthony Dubernet, Arthur Rakoto, Mahary Lalarizo Seteyen, Anne-Laure Sandenon Vagner, Damien Lebeau, Grégorie Raffray, Loïc Gasque, Philippe Immunol Res Brief Report Springer US 2022-06-09 2022 /pmc/articles/PMC9178219/ /pubmed/35679009 http://dx.doi.org/10.1007/s12026-022-09269-w Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| spellingShingle | Brief Report Dobi, Anthony Dubernet, Arthur Rakoto, Mahary Lalarizo Seteyen, Anne-Laure Sandenon Vagner, Damien Lebeau, Grégorie Raffray, Loïc Gasque, Philippe Low levels of the key B cell activation marker, HLA-DR, in COVID-19 hospitalized cases are associated with disease severity, dexamethasone treatment, and circulating IL-6 levels |
| title | Low levels of the key B cell activation marker, HLA-DR, in COVID-19 hospitalized cases are associated with disease severity, dexamethasone treatment, and circulating IL-6 levels |
| title_full | Low levels of the key B cell activation marker, HLA-DR, in COVID-19 hospitalized cases are associated with disease severity, dexamethasone treatment, and circulating IL-6 levels |
| title_fullStr | Low levels of the key B cell activation marker, HLA-DR, in COVID-19 hospitalized cases are associated with disease severity, dexamethasone treatment, and circulating IL-6 levels |
| title_full_unstemmed | Low levels of the key B cell activation marker, HLA-DR, in COVID-19 hospitalized cases are associated with disease severity, dexamethasone treatment, and circulating IL-6 levels |
| title_short | Low levels of the key B cell activation marker, HLA-DR, in COVID-19 hospitalized cases are associated with disease severity, dexamethasone treatment, and circulating IL-6 levels |
| title_sort | low levels of the key b cell activation marker, hla-dr, in covid-19 hospitalized cases are associated with disease severity, dexamethasone treatment, and circulating il-6 levels |
| topic | Brief Report |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9178219/ https://www.ncbi.nlm.nih.gov/pubmed/35679009 http://dx.doi.org/10.1007/s12026-022-09269-w |
| work_keys_str_mv | AT dobianthony lowlevelsofthekeybcellactivationmarkerhladrincovid19hospitalizedcasesareassociatedwithdiseaseseveritydexamethasonetreatmentandcirculatingil6levels AT dubernetarthur lowlevelsofthekeybcellactivationmarkerhladrincovid19hospitalizedcasesareassociatedwithdiseaseseveritydexamethasonetreatmentandcirculatingil6levels AT rakotomaharylalarizo lowlevelsofthekeybcellactivationmarkerhladrincovid19hospitalizedcasesareassociatedwithdiseaseseveritydexamethasonetreatmentandcirculatingil6levels AT seteyenannelauresandenon lowlevelsofthekeybcellactivationmarkerhladrincovid19hospitalizedcasesareassociatedwithdiseaseseveritydexamethasonetreatmentandcirculatingil6levels AT vagnerdamien lowlevelsofthekeybcellactivationmarkerhladrincovid19hospitalizedcasesareassociatedwithdiseaseseveritydexamethasonetreatmentandcirculatingil6levels AT lebeaugregorie lowlevelsofthekeybcellactivationmarkerhladrincovid19hospitalizedcasesareassociatedwithdiseaseseveritydexamethasonetreatmentandcirculatingil6levels AT raffrayloic lowlevelsofthekeybcellactivationmarkerhladrincovid19hospitalizedcasesareassociatedwithdiseaseseveritydexamethasonetreatmentandcirculatingil6levels AT gasquephilippe lowlevelsofthekeybcellactivationmarkerhladrincovid19hospitalizedcasesareassociatedwithdiseaseseveritydexamethasonetreatmentandcirculatingil6levels |